Visual prosthetic device for bilateral end-stage macular degeneration

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Medical Devices

Background:

• Age-related macular degeneration (AMD) is a primary cause of irreversible blindness in the USA.
• Advanced stages of AMD affect 1.8 million patients, with no current treatments to restore vision.
• The central vision impairment significantly impacts patients' quality of life.

Purpose of the Study:

• To evaluate the efficacy of a novel intraocular visual prosthetic device designed to improve central vision in patients with bilateral end-stage AMD.
• To assess the impact of the device on visual impairment levels and overall quality of life.

Main Methods:

• A visual prosthetic device was developed to provide an enlarged retinal image to one eye, while the other eye retains peripheral vision.
• The device is designed for implantation in the posterior chamber via an outpatient surgical procedure.
• US Food and Drug Administration (FDA) clinical trials were conducted to assess safety and efficacy.

Main Results:

• 72% of patients demonstrated improvement in their level of visual impairment, moving from profound/severe to severe/moderate categories.
• A clinically significant enhancement in the quality of life was observed in the patient cohort.
• The device was successfully implanted in an outpatient setting.

Conclusions:

• The intraocular visual prosthetic device shows promise as a treatment option for vision restoration in end-stage AMD.
• The device can significantly improve visual function and quality of life for patients with limited therapeutic options.
• Further investigation and adoption of this technology could address a critical unmet need in AMD treatment.